Investigational Drug Information for VS-6063
✉ Email this page to a colleague
What is the drug development status for VS-6063?
VS-6063 is an investigational drug.
There have been 18 clinical trials for VS-6063.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 12th 2015.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Lung Neoplasms. The leading clinical trial sponsors are Verastem, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.
There are seventeen US patents protecting this investigational drug and two hundred and one international patents.
Summary for VS-6063
| US Patents | 17 |
| International Patents | 201 |
| US Patent Applications | 147 |
| WIPO Patent Applications | 129 |
| Japanese Patent Applications | 44 |
| Clinical Trial Progress | Phase 2 (2015-08-12) |
| Vendors | 58 |
Recent Clinical Trials for VS-6063
| Title | Sponsor | Phase |
|---|---|---|
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | National Cancer Institute (NCI) | Phase 2 |
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | Verastem, Inc. | Phase 2 |
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | Washington University School of Medicine | Phase 2 |
Clinical Trial Summary for VS-6063
Top disease conditions for VS-6063
Top clinical trial sponsors for VS-6063
US Patents for VS-6063
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| VS-6063 | See Plans and Pricing | Gene fusions and gene variants associated with cancer | LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) | See Plans and Pricing |
| VS-6063 | See Plans and Pricing | Methods of diagnosing and treating B cell acute lymphoblastic leukemia | The General Hospital Corporation (Boston, MA) Tufts Medical Center, Inc. (Boston, MA) | See Plans and Pricing |
| VS-6063 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| VS-6063 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for VS-6063
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| VS-6063 | Australia | AU2014254394 | 2033-04-17 | See Plans and Pricing |
| VS-6063 | China | CN105378110 | 2033-04-17 | See Plans and Pricing |
| VS-6063 | China | CN106414768 | 2033-04-17 | See Plans and Pricing |
| VS-6063 | European Patent Office | EP2986736 | 2033-04-17 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
